BHV 4157

Drug Profile

BHV 4157

Alternative Names: BHV-4157

Latest Information Update: 26 Dec 2016

Price : $50

At a glance

  • Originator Yale University
  • Developer Biohaven Pharmaceutical Holding Company
  • Class Benzothiazoles; Small molecules
  • Mechanism of Action Glutamate modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Spinocerebellar degeneration
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II/III Spinocerebellar degeneration

Most Recent Events

  • 22 Dec 2016 Phase-II/III clinical trials in Spinocerebellar degeneration (spinocerebellar ataxia) in USA (PO) (NCT02960893)
  • 20 Jul 2016 Clinical trials in Spinocerebellar degeneration in USA (PO)
  • 05 Jul 2016 US FDA approves IND application for a phase III trial in Spinocerebellar degeneration
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top